Skip to main content
    B

    Bio-Rad Laboratories Inc (BIO-B)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $389.98
    +0.00 (+0.00%)

    Market Cap: $10.49B

    Last updated: Nov 16, 2026 at 4:10 PM ET

    Bio-Rad Laboratories Inc (BIO-B) P/E Ratio & Valuation History

    Updated Nov 16, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Bio-Rad Laboratories (BIO-B) trades at 10.3x trailing earnings and 4.1x sales. Its P/E of 10.3x is below its 10-year median of 46.7x. Its forward P/E is 40.8x. The median P/E across 9 similar companies is 23.9x.

    Current Multiples

    Its forward P/E is above its trailing P/E, which implies earnings per share about 74.8% lower over the next year. Its free cash flow yield is 3.1%.

    MultipleValue
    P/E (trailing)10.3x
    Forward P/E40.8x
    Price to sales4.1x
    Price to book1.4x
    EV/EBITDA7.6x
    Price to FCF31.9x
    EV/FCF34.2x
    PEG1.2
    FCF yield3.1%
    As of Nov 16, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 7.9% above 3.8x and its P/B is 12.5% below 1.6x.

    MultipleCurrent5-year median10-year median
    P/E10.3xN/A46.7x
    P/S4.1x3.7x3.8x
    P/B1.4x1.2x1.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 105 to 120 months (10-year).

    Valuation History

    Over the 9 of the 10 year ends shown that have a P/E, its P/E ranged from 11.1x in 2025 to 192.8x in 2016. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$310.7011.1x3.3x1.1x
    2024$325.60N/A3.6x1.4x
    2023$320.6527.2x3.5x1.1x
    2022$404.6628.4x4.3x1.3x
    2021$722.9146.1x7.5x1.6x
    2020$574.1554.5x6.8x1.8x
    2019$369.6051.7x4.8x1.9x
    2018$230.0039.3x3.0x1.7x
    2017$238.25118.5x3.3x2.4x
    2016$183.15192.8x2.6x2.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BIO-B

    What is BIO-B's forward P/E ratio?

    Bio-Rad Laboratories has a forward P/E ratio of 40.8x.

    Is BIO-B stock overvalued?

    GNG's valuation label for BIO-B is Undervalued. Its P/E of 10.3x compares with a median of 23.9x across 9 similar companies.

    What is BIO-B's price to sales ratio?

    Bio-Rad Laboratories has a price to sales ratio of 4.1x.

    What is Bio-Rad Laboratories's average P/E ratio over 10 years?

    Bio-Rad Laboratories's median P/E over the last 10 years is 46.7x, from 105 month-end values through Oct 2026.

    What is BIO-B's PEG ratio?

    Bio-Rad Laboratories has a PEG ratio of 1.2.